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ABSTRACT:
High-grade  astrocytoma  remains  a  significant  challenge  to  the  clinician  and 
researcher alike. Intense study of the molecular pathogenesis of these tumors has 
allowed identification of frequent genetic alterations and critical core pathways 
in this disease. The use of novel mouse genetic tools to study the consequence of 
specific mutations in brain has led to the development of multiple representative 
genetically engineered mouse models that provided novel insights into gliomagenesis. 
As we learn more about the biology of high-grade astrocytoma from the study of 
these models, we anticipate that our improved understanding will eventually 
lead to greater success in clinical trials and improved outcome for patients. 
INTRODUCTION
High-Grade Astrocytomas (HGAs) are among the 
most aggressive and deadly malignancies in man. Unlike 
most cancers, these primary central nervous system (CNS) 
tumors do not achieve their lethality by metastatic spread 
to secondary organs, leading to overwhelming tumor 
burden and multiorgan failure in patients. The devastating 
effects of HGAs can be traced to multiple contributing 
factors. 1) The brain is encased within a solid cranial 
vault such that progressive tumor expansion leads not 
only to specific neurological signs and symptoms but 
also to generalized CNS depression and dysfunction. 2) 
Tumors are often localized within or adjacent to critical 
brain structures making complete surgical resection 
neurologically devastating and therefore impossible. 3) 
HGAs are highly invasive such that even in cases where 
complete radiographic resection is achieved local and/or 
distant microscopic spread of tumor cells at the time of 
diagnosis usually leads to rapid tumor regrowth. 4) Tumor 
cells and in particular glioma stem-like cells exhibit a high 
degree of radio and chemoresistance due to both intrinsic 
(eg. tumor heterogeneity, rapid mutational adaptation) 
and extrinsic (eg. blood-brain barrier) mechanisms. As a 
consequence, despite contemporary multimodal therapy 
that includes aggressive surgery, maximally delivered 
radiotherapy and temozolomide, median overall survival 
for glioblastoma, the most advanced form of HGA, is 15-
18 months, a dismal prognosis which has not significantly 
improved in several decades [1, 2]. It would appear 
that further incremental improvements in neurosurgery, 
radiation therapy and conventional chemotherapy will 
have minimal impact on this disease. Therefore novel 
therapeutic modalities and agents are desperately required 
to improve patient outcome.
This persistently bleak clinical outlook for HGA has 
led to the viewpoint that the traditional laboratory models 
used to study disease biology and to conduct pre-clinical 
trials are not adequately representative of the human 
condition. Concurrently, technical advancements in the 
manipulation of mouse genetics have resulted in the recent 
development of several novel genetically engineered 
mouse models (GEMMs) for HGA. Accumulating 
evidence suggests that these models faithfully recapitulate 
the histology and molecular biology of HGA and therefore, 
they may provide new insights towards understanding 
the aggressive nature of this malignancy and lead to the 
development and testing of novel therapeutic strategies. 
Herein, we review the main concepts that define HGA 
molecular pathology, present a selection of GEMMs 
that echo these concepts and outline directions in which 
translational applications are being applied.Oncotarget 2012; 3:  67 - 77 68 www.impactjournals.com/oncotarget
CORE PATHWAY MUTATIONS IN HIGH-
GRADE ASTROCYTOMAS
Gliomas  are  diffusely  infiltrating  tumors  of  the 
CNS that encompass a spectrum of histologically distinct 
but overlapping neoplasms. The current World Health 
Organization  (WHO)  classification  scheme  reflects 
this heterogeneity and segregates tumors according to 
their grade and predominant histological features [3]. 
Astrocytic tumors are the largest histological group 
and can occur at all grade levels from 1 to 4. Grade 1 
astrocytoma, also referred to as pilocytic astrocytoma 
appears to have a molecular etiology unrelated to other 
astrocytic tumors and behaves clinically as a distinct 
entity [4]. The remaining grades of astrocytomas lie 
along a spectrum of histopathology demonstrating 
progressively more aggressive features that culminate in 
grade 4 tumors known as glioblastoma [3]. Low grade or 
diffuse astrocytomas are grade 2 tumors that frequently 
undergo malignant transformation leading to disease 
recurrence in patients as HGAs (grade 3 or 4). Less 
than 10% of glioblastomas arise in this manner, and are 
termed secondary glioblastomas. Primary glioblastomas 
comprise the vast majority of glioblastomas, and occur in 
the absence of an antecedent low grade lesion. Genome-
wide and integrative genomic analyses have resulted in 
the identification of molecularly defined and biologically 
distinct tumor subgroups.
Many frequently mutated tumor suppressor genes 
and oncogenes in HGA are associated with recurrent 
chromosomal aberrations. Notable examples include loss 
of heterozygosity (LOH) and inactivating point mutations 
of the tumor suppressor genes TP53 [5, 6] and PTEN 
[7, 8], homozygous deletions of CDKN2A [9-11], and 
amplification with or without activating mutations of the 
oncogene EGFR [12, 13]. More recently, investigators 
used genome-wide approaches to catalog the genetic 
changes in HGA [14, 15]. These groundbreaking studies 
have led to the current concept that most if not all HGAs 
are characterized by dysregulation of three core pathways: 
the receptor tyrosine kinase (RTK)/phosphatidylinositol 
3’-kinase (PI3K)/AKT axis, p53 signaling and RB-
mediated control of cell cycle progression (Figure 1). 
These studies also validated the importance of NF1 
inactivation in non-syndromic HGA and identified novel 
players in gliomagenesis, such as PIK3R1 and IDH1 
whose mechanism of action is the subject of intense 
investigation [16].
The RTK/PI3K/AKT pathway regulates many 
aspects of cellular physiology including proliferation, 
protein translation, cell size, cell survival, cell migration 
and motility, all of which have been implicated in 
the malignant phenotype (Figure 1) [17]. The precise 
outcome of pathway activation is strictly context 
dependent and it is not entirely clear which of these 
effects are most important during gliomagenesis. This 
pathway is targeted for mutational activation at multiple 
nodes [14, 15]. Amplifications and activating mutations 
of the RTK genes EGFR, PDGFRA, ERBB2 and MET 
are seen in 59% of HGAs. The EGFR gene is by far the 
most commonly activated oncogene in HGA. Another 
commonly targeted node in this pathway is the production 
of the secondary messenger molecule phosphatidylinositol 
(3,4,5)-trisphosphate (PIP3). Three critical genes 
regulating this process are targeted for mutation: PIK3CA 
and PIK3R1, which encode the catalytic and regulatory 
subunits of Class 1A PI3K respectively, and PTEN, the 
gene encoding the lipid phosphatase that opposes PI3K 
activity. Together, these genes are mutated in 49% of 
HGAs. Mutations and homozygous deletions of the 
NF1 gene are present in 18% of tumors [14, 15]. NF1 
contains a GTP-ase activating protein (GAP) domain and 
is thought to exert tumor suppressive activity primarily 
by inactivation of RAS proteins. Interestingly, neither 
study found significant activating mutations of RAS or 
RAF family members, which are commonly targeted 
oncogenes in tumors driven by RAS/MAPK signaling 
such as pilocytic astrocytoma, lung and colon carcinomas 
and melanoma [4, 18-20]. This suggests that the primary 
outcome of NF1 inactivation may be to boost PI3K/AKT 
signaling via crosstalk between pathways, which has been 
demonstrated in glioma GEMMs (see below). Finally, 
members of the AKT family are infrequently targeted 
for gene amplifications. Notably, there is an absence of 
mutations in downstream effectors of AKT suggesting 
that multiple effectors of the pathway may play critical 
roles in gliomagenesis. Alternatively, such mutations 
may have a net deleterious effect on tumor growth due 
to the existence of feedback inhibition circuits. These 
are all potentially critical considerations when selecting 
appropriate inhibitors of the RTK/PI3K/AKT pathway for 
HGA therapy.
TP53 is the most commonly mutated tumor 
suppressor gene in human cancer. The P53 pathway 
regulates the critical checkpoint that detects oncogenic 
stress and DNA damage, which if unresolved leads to 
cellular senescence or apoptosis (Figure 1). In HGA, 
the  TP53 gene along with genes encoding regulators 
of p53 stability (MDM2, MDM4 and CDKN2A which 
encodes p19ARF) are targeted in at least 87% of cases 
[14]. Therapeutic strategies aimed at stabilizing p53 via 
inhibition of MDM2 and/or MDM4 are predicted to be 
effective in tumors with intact p53 function, therefore 
characterization  of  specific  pathway  mutations  is 
potentially important.
The RB family, and in particular phosphorylation 
of its primary member RB1, regulates the cell cycle 
checkpoint at the G1/S boundary (Figure 1). The INK4 
family of proteins negatively regulates the phosphorylation 
of RB by suppressing a complex containing D-type 
Cyclins and the Cyclin-dependent kinases CDK4 or 
CDK6. While RB1 itself is deleted or mutated in 11% of Oncotarget 2012; 3:  67 - 77 69 www.impactjournals.com/oncotarget
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Figure 1: Frequency of pathway mutations in high-grade astrocytoma. The frequency of mutations affecting intermediates 
of several pathways is indicated in parentheses. Proteins whose genes are amplified or have an activating mutation are represented in red 
while those whose genes are deleted or have an inactivating mutation are in blue. The proteins are grouped according to the core pathways 
in which they function (dotted lines). The IDH1 mutant proteins (IDH1*) possess a neomorphic catalytic activity which is depicted. The 
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HGAs, its upstream regulation is more frequently targeted 
with CDKN2A and CDKN2B, which encode INK4A and 
INK4B respectively, being homozygously deleted in 47% 
of tumors [14]. CDK inhibitors under development would 
not be expected to have an effect on tumors in which RB1 
or downstream effectors are mutated.
Using an unbiased approach to sequence nearly 
all of the protein-coding exons in the genome, Parsons 
et al. identified novel mutations in the IDH1 gene in 
11% of HGAs (Figure 1) [15]. Strikingly, these tumors 
were all secondary glioblastomas and the presence of 
mutations was associated with a better overall outcome. 
Subsequent characterizations of much larger cohorts 
of  patients  have  confirmed  these  associations  and 
clearly implicate IDH1 mutation and to a lesser extent 
mutations in the mitochondrial isoform, IDH2, as an 
early event in gliomagenesis [21, 22]. Interestingly, the 
overwhelming majority of mutations occur at a single 
amino acid residue (R132 in IDH1 and R172 in IDH2) 
which appears to confer a neo-catalytic activity to these 
proteins. While the native enzyme catalyzes the oxidative 
decarboxylation of isocitrate to α-ketoglutarate, the mutant 
form is able to catalyze the reduction of α-ketoglutarate to 
2-hydroxyglutarate in an NADPH-dependent process [23, 
24]. At present, the mechanism of mutant IDH1-initiated 
gliomagenesis is not known, however the consequences 
of its neo-catalytic activity to cellular metabolic pathways 
that may promote oncogenesis have been discussed [25, 
26].
GENE EXPRESSION SIGNATURES IN 
HIGH-GRADE ASTROCYTOMAS
Whole transcriptome analysis has emerged as an 
important method to compare tumor samples and may 
lead to improved patient stratification and determination 
of prognosis. This method was used to define expression 
signatures that distinguish HGA patients according to 
differential survival outcomes in two independent studies 
[27, 28]. In both cases, a subgroup of tumors, termed 
Proneural, expresses genes associated with neurogenesis 
and  was  found  to  have  a  significantly  better  survival 
compared to the remaining tumors. Poor outcome 
tumors can be subdivided into at least two groups: one 
expressing markers of angiogenesis and mesenchymal 
cells (Mesenchymal subgroup) while another expresses 
an abundance of genes associated with mitosis and 
proliferation (Proliferative subgroup). Building on 
these results, Verhaak et al. analyzed the multiplatform 
glioblastoma data from the Cancer Genome Atlas 
Research Network [29]. Unsupervised gene expression 
analysis identified similar Proneural and Mesenchymal 
HGA subgroups along with two other subgroups which 
they termed Neural and Classical. A recent comparison of 
subgroups defined by these two approaches demonstrated 
that the subgroups with the strongest identity were the 
Proneural and Mesenchymal signatures [30]. Integrated 
analysis of gene expression signatures and genomic 
mutation data [14] showed that the majority of tumors 
with IDH1 mutations as well as PDGFRA amplifications 
and activating mutations clustered with the Proneural 
subgroup [29]. In contrast, NF1 mutations, LOH and 
loss of expression were more highly associated with 
Mesenchymal tumors. Finally, the Classical subgroup was 
characterized by frequent amplifications and mutations 
of the EGFR gene (including the EGFRvIII variant) and 
strikingly, by the absence of TP53 mutations. The mutual 
exclusivity of HGAs with PDGFR-α expression, EGFR 
expression and loss of NF1 was also seen in a targeted 
proteomic study [31].
Ultimately, the goals of genome-wide and integrative 
genomic analyses are to provide a template for accurate 
molecular  classification  of  HGA  that  will  be  highly 
predictive for prognosis and can be used to stratify patients 
for optimal therapy.
PEDIATRIC HIGH-GRADE GLIOMAS ARE 
RELATED BUT MOLECULARLY DISTINCT 
FROM ADULT HGA
While the same WHO criteria apply to the 
classification of pediatric high-grade gliomas (HGGs), 
several differences in the clinical behavior of patients hint 
at fundamental differences that may exist in tumor biology. 
1) Malignant transformation of low-grade astrocytomas 
in children has been described but appears to occur at a 
much lower frequency than observed in adult patients 
[32]. 2) A significant proportion of pediatric HGGs occur 
in the brainstem (diffuse intrinsic pontine glioma) or in 
the thalamus (bithalamic glioma) [4], locations rarely 
encountered in adults. 3) The addition of temozolomide 
to standard irradiation confers a survival advantage albeit 
modest to adults with HGA while this does not appear to 
be the case in children [33]. Directed analyses of genes 
commonly mutated in adult HGA revealed that mutations 
and losses of TP53 [34] and CDKN2A [35] occur with 
relative frequency while mutations and losses of PTEN 
and in particular amplifications of the EGFR gene are 
rare in pediatric HGG [36]. These observations were 
largely corroborated in large genome-wide analyses of 
chromosomal aberrations [37-40]. The most common 
focal amplification and deletion respectively were high-
level amplification of PDGFRA (14%) and homozygous 
deletion of CDKN2A (16%). IDH1 hotspot mutations are 
not common in pediatric HGG [39, 41]. Overall, unlike 
adult tumors there is a lack of high frequency genetic 
targets in pediatric HGG.
Unsupervised  gene  expression  analysis  identified 
three subgroups corresponding to the Proneural, 
Proliferative and Mesenchymal subclasses seen in adult 
HGA [39]. However, with the exception of PDGFRA 
amplifications  which  clustered  in  the  Proliferative Oncotarget 2012; 3:  67 - 77 71 www.impactjournals.com/oncotarget
subgroup (and not in the Proneural group as in adults) 
there was little correlation between focal genetic 
aberrations and specific subgroups. Furthermore, copy 
number alterations targeting genes within core pathways 
were clearly present in pediatric HGG at lower frequency 
than in adult tumors. This suggests that these tumors 
utilize alternative mechanisms to dysregulate the pathways 
or that core pathways play a diminished role in pediatric 
HGG. Collectively, these studies show similar gene 
expression-defined subgroups in pediatric and adult HGGs 
that are driven by a different set of low-frequency genetic 
events in children.
MODELING CORE PATHWAY MUTATIONS 
IN HGA
As our understanding of genetic abnormalities 
underlying HGAs becomes more comprehensive, 
increasingly complex GEMMs have been developed to 
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PN – Proneural; Prolif – Proliferative; Mes - Mesenchymal
Table 1: Comparison of genetically engineered mouse modelsOncotarget 2012; 3:  67 - 77 72 www.impactjournals.com/oncotarget
investigate the contribution and interplay between driver 
mutations (Table 1). Several models have addressed the 
relative contribution of core pathways in gliomagenesis. 
By using an inducible GFAP-CreER conditional mouse 
line that drives loxP-dependent recombination in 
astrocytes and adult neural precursors, cooperativity 
between the three tumor suppressor genes, Trp53, Pten 
and Rb1, for gliomagenesis was explored in the context of 
the adult brain [42]. This study demonstrated that deletion 
of Pten alone or in combination with Rb1 was unable to 
initiate glioma formation. In contrast, Trp53 deletion in 
conjunction with loss of the Pten or Rb1 tumor suppressor 
gene resulted in high frequency HGA, while deletion of 
Trp53 alone resulted in HGA with low frequency and 
with prolonged latency. The importance of concurrent 
dysregulation of the three core pathways was confirmed as 
HGAs resulting from targeted deletion of Trp53 and Pten 
acquired secondary mutations in Rb pathway genes while 
Pi3k/Akt pathway activation was seen in tumors arising 
from Rb1 and Trp53 conditional ablation. Accordingly, 
mice engineered with targeted deletion of all three tumor 
suppressor genes developed HGA with a significantly 
reduced latency.
Using a different approach to target tumor suppressor 
genes for deletion in post-natal neural progenitor cells 
resulted in divergent results. Cre-expressing adenovirus 
was directly injected into the lateral ventricle of mice 
carrying various combinations of floxed tumor suppressor 
gene alleles [43]. Only the combination of Trp53 and 
Pten co-deletion resulted in the development of HGA 
in mouse brains whereas combined deletion of Trp53 
and Rb1 or all three together generated primitive neuro-
ectodermal tumors (PNETs). Interestingly, overexpression 
of Cdk4 was present in the Trp53; Pten deleted HGAs 
demonstrating that Rb-mediated regulation of cell-
cycle progression is a core pathway in these tumors. 
The selective advantage for the development of PNET 
in this setting likely reflects a less specific manner in 
which cells are targeted for Cre-mediated recombination. 
Indeed, accumulating experimental evidence indicates 
that different types of brain tumors, and even different 
subgroups within a histological diagnosis, arise as a 
consequence of specific driver mutations occurring in 
specific susceptible cell populations [44, 45]. It follows 
that for relatively promiscuous driver mutations such as 
loss of Trp53, Rb1 or Pten, the cell being targeted as well 
as the developmental context in which mutations occur, 
are likely to be critical determinants of the resulting tumor 
type.
The importance of developmental context is apparent 
in a study in which an intragenic deletion of Trp53 in 
embryonic neural stem cells was mediated by a GFAP-Cre 
transgene [46]. HGAs were primarily observed however, 
a discernible fraction of tumors that developed were 
medulloblastomas, likely arising from progenitor cells 
targeted in the developing mouse brain. In agreement with 
the two previously mentioned studies the HGAs described 
in these mice also demonstrated dysregulation of the Rb 
and RTK/Pi3k/Akt pathways. 
The contributions of various intermediates of the 
RTK/Pi3k/Akt pathway have been explored in GEMMs. 
Consistent with the finding that Pten deletion alone does 
not lead to gliomagenesis, activation of other pathway 
intermediates  on  their  own  is  similarly  inefficient  at 
initiating HGAs. Neither virally-induced expression 
of the activated EGFR variant, EGFRvIII [47], nor 
PDGF-B in adult neural progenitor cells [48] was 
sufficient on their own to initiate HGA. However, when 
coupled with germ-line deletion of Cdkn2a and deletion 
of Pten in the striatum, EGFRvIII expression resulted 
in robust tumor formation [47]. Likewise, germ-line 
deletion of Cdkn2a or Trp53 coupled with expression of 
PDGF-B efficiently initiated HGAs in adult mice [48]. 
Underscoring the differences between adult and pediatric 
tumor biology, when PDGF-B was expressed by targeted 
viral transduction into neonatal neural progenitors, many 
mice developed low grade gliomas while a small number 
harbored HGGs [49]. The proportion and aggressiveness 
of HGGs were greatly enhanced by germ-line loss of the 
Cdkn2a gene but not by Trp53 deletion.
The role of the Nf1 tumor suppressor gene in 
gliomagenesis has also been investigated using GEMMs. 
Conditional ablation of the gene in the developing brain 
using a GFAP-Cre driver mouse line was insufficient to 
initiate gliomagenesis [50] however, when paired with 
germ-line or conditional deletion of Trp53, malignant 
gliomas were efficiently produced [51, 52]. As in the other 
models discussed, tumors in this context demonstrated 
Rb pathway dysregulation as demonstrated by robust 
expression of Cdk4 and Cyclin D1 [52]. Interestingly, the 
Pi3k/Akt pathway was significantly activated in Nf1-null 
HGAs implying crosstalk between these downstream RTK 
effectors. Furthermore, loss of the Pten tumor suppressor 
enhanced gliomagenesis in this model [51]. These 
investigators subsequently showed that deletion of Nf1 and 
Trp53 with or without Pten loss in adult neural progenitors 
gave rise to HGAs [53]. 
Collectively, these results support the notion that 
three core pathways play critical roles in human and 
mouse HGA. The experimental evidence that loss of 
p53 function, but not Pten or Rb, contributes to early 
stages of gliomagensis in mice is consistent with the 
elevated incidence of astrocytomas in individuals with Li-
Fraumeni syndrome but neither in Pten Hamartoma Tumor 
Syndrome (PHTS) nor in patients with germline RB1 
mutations [54-56]. Furthermore, mutations in TP53, but 
not PTEN or RB1, are found in low-grade astrocytomas 
prior to malignant transformation [57]. Therefore, loss 
of TP53 would appear to be an early mutation in both 
primary and secondary glioblastoma.Oncotarget 2012; 3:  67 - 77 73 www.impactjournals.com/oncotarget
GEMMS RECAPITULATE MOLECULAR 
PATHOLOGY OF HGAS
All of the GEMMs described reproduce human 
histological features characteristic of aggressive HGAs. 
However, molecularly targeted therapies are now the 
focus of many clinical HGA trials with the expectation 
that they will eventually augment or replace our current 
treatment regimens. It is therefore critically important 
for preclinical models of the disease to mirror not only 
the histology of human astrocytomas but also their 
molecular pathology. To address this, tumors arising from 
adult mouse brains with targeted deletions of Trp53 and 
Pten or Trp53, Pten and Rb1 were subjected to genome-
wide molecular profiling [42]. These analyses revealed 
striking similarities to human HGAs at both the genomic 
and transcriptomic levels. Array comparative genomic 
hybridization (aCGH) identified focal as well as large-
scale chromosomal amplifications and losses characteristic 
of  human  HGAs.  Focal  amplifications  included  those 
targeting the RTK genes Met, Pdgfra and Egfr and genes 
encoding the upstream Rb regulators Cdk4, Cdk6 and 
Ccnd1. Meanwhile, gene expression analyses segregated 
tumors into three subgroups with significant identity to 
the Proneural, Proliferative and Mesenchymal subgroups 
defined by human glioblastoma gene expression studies 
[28, 29].
It is particularly interesting to note that in these 
murine astrocytomas, multiple mutations within core 
pathways were frequently observed [42]. RTK gene 
amplifications were noted in both Trp53 and Pten as well 
as in Trp53, Pten and Rb1 mutated tumors. Importantly, 
these amplifications appeared to drive maximal signaling 
through the Pi3k pathway suggesting that ablation of 
Pten function, the principal negative regulator of Pi3k 
signaling, is not sufficient to activate the pathway. HGAs 
with concurrent mutations of PTEN and RTK genes have 
been noted in several studies [14, 58]. Furthermore, 
several murine astrocytomas were characterized by 
co-amplifications of more than one RTK gene [42], a 
phenomenon that has also been appreciated in human 
tumors [14, 59, 60]. In similar observations, multiple 
mutations affecting Rb pathway signaling were observed 
in both mouse [42] and human HGAs [14, 59]. These 
observations have important implications for the selection 
of targeted agents and suggest that pathway inhibition 
at multiple nodes may be required to achieve maximal 
therapeutic effect.
A recent study employed a retrovirus encoding 
PDGF-B and the Cre recombinase which was directly 
injected into the subcortical white matter of adult mice 
[61]. HGAs arose efficiently in mice in which Pten or 
the combination of Pten and Trp53 were conditionally 
targeted. Gene expression analyses revealed that all 
tumors expressed a signature strongly associated with the 
Proneural subgroup which is consistent with PDGFRA 
amplified  tumors  in  adults  [29,  31]. The  authors  also 
used the mouse HGA expression profiles to identify two 
groups of patients with Proneural tumors with significantly 
different survival outcomes [61].
These studies demonstrate that GEMM HGAs can 
recapitulate not only tumor histology accurately but also 
their molecular pathology. Depending on their design, the 
models can replicate a spectrum of human HGA subtypes 
or phenocopy specific ones [42, 61]. As GEMMs are 
increasingly incorporated into preclinical therapeutic 
trials [62], a comprehensive understanding of each one’s 
molecular characteristics will be required to translate the 
results into effective clinical trial designs.
USING GEMMS TO TRACE THE CELL-OF-
ORIGIN OF HGAS
GEMMs offer a unique opportunity to analyze 
the early events of gliomagenesis which cannot be 
accurately determined in studies of human tumors or with 
xenograft models. Careful analysis of early time points 
in these mouse models coupled with clever tools to trace 
transformed cells has resulted in a refined understanding 
of the cell-of-origin of astrocytomas. By analyzing cells 
that accumulate mutant p53 soon after Cre-mediated 
recombination, Wang et al. suggest that HGAs in their 
model originate from the Gfap-positive neural precursor 
cell (NPC) in the subventricular zone and/or from Olig2-
expressing progenitor-like cells most commonly found in 
the corpus callosum [46].
However, a recent report utilized the same GFAP-
Cre driver line in conjunction with an elegant genetic tag 
to label cells that had undergone homozygous deletion 
of Trp53 and Nf1 [63]. These investigators demonstrated 
that while tumor suppressor deletion occurred in the NPC, 
these cells remained quiescent until after differentiation 
into oligodendrocyte precursor cells (OPCs) when they 
acquired a proliferative phenotype associated with cellular 
transformation. Similarly, the OPC was also implicated as 
the transforming cell type in experiments where mutant 
cells were retrovirally labeled [61]. Interestingly, in the 
latter study, viral injections were targeted to subcortical 
white matter and not to the subventricular zone. Clearly, 
GEMMs using both virally delivered Cre and mouse Cre-
expressing lines have demonstrated that HGAs can arise 
outside of the canonical adult neural progenitor cell niches 
[42, 47, 48]. The nature of the tumor initiating cell has yet 
to be rigorously investigated in these models.
These results highlight the differences in 
experimental approach between the various GEMMs 
and what we can learn from their use (Table 1). Targeted 
delivery of viruses to specific brain regions can be used to 
label relatively few cells and may be an ideal approach to 
identify and study certain tumor initiating cells. However, 
tumors initiating from deep seated regions of the brain or 
from less common sites or cell types may not be efficiently Oncotarget 2012; 3:  67 - 77 74 www.impactjournals.com/oncotarget
targeted by this approach. The use of Cre mouse lines like 
GFAP-Cre that have activity in the vast pool of embryonic 
neural stem cells allow for the study of early events of 
tumorigenesis in these cells and their derivatives. Due 
to this embryonic activity, there is a strong bias in these 
models for transformation of the embryonic neural stem 
cell population over more mature cell types. The GFAP-
CreER driver line allows for widespread and unbiased 
genetic manipulation in mature astrocytes and progenitor 
cells from all regions of the central nervous system and 
has revealed tumor formation in non-proliferative zones 
such as the cortex, brain stem, cerebellum and spinal 
cord. It is important to note that human HGAs arise 
predominantly in these non-proliferative regions of the 
brain. However, identifying the cell-of-origin in these 
models is challenging and will require additional genetic 
markers. Further study of these different GEMMs will 
continue to contribute to our understanding of HGA 
initiation and progression.
THE PROSPECTS FOR HGA GEMMS TO 
IMPACT PATIENT OUTCOME
HGA continues to be one of the most challenging 
malignancies that patients and clinicians face. It is clear 
that substantial improvements in neurosurgical techniques, 
perioperative care and delivery of radiotherapy have 
failed to appreciably improve patient outcome [57]. 
Likewise, conventional chemotherapy has only succeeded 
in producing a modest clinical impact. As molecularly 
targeted therapy continues to make inroads in the practice 
of contemporary clinical oncology, it is anticipated that 
these approaches will also prove beneficial for HGA. 
Preclinical investigations will have maximal impact 
if they employ a series of molecularly characterized 
animal models that are collectively representative of gene 
expression and pathway mutation subgroups (Figure 2). 
Only by systematically testing new molecularly targeted 
agents against the panel of models will we understand 
how pharmacologic pathway manipulations differentially 
impact the biology of HGA subgroups. Such studies could 
Figure 2: Framework for translational research using genetically engineered mouse models (GEMMs) for high-grade 
astrocytoma (HGA). Tumors arising in HGA GEMMs are subjected to genome-wide analyses (array comparative genomic hybridization, 
gene expression, microRNA expression). The status of signaling pathways are determined by western blots or immunohistochemistry. 
These data are analyzed integratively and can be compared to similar data obtained from human HGAs to identify critical driver mutations, 
pathways and biomarkers of disease. Candidate genes can be validated in novel GEMMs while biomarkers can be queried either 
retrospectively or prospectively in clinical trials. Identified pathways with known inhibitors can be tested in the GEMMs using various 
readouts of efficacy. Promising agents or combinations are carried forward into clinical trials. These in turn will lead to banking and further 
studies of HGA tumor samples.
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be facilitated by increased cooperation between industry 
and academia as well as between different investigators 
working with GEMMs. We anticipate that the knowledge 
gained from such efforts will help predict which 
combinations of agents may be beneficial for specific 
patient subgroups and lead to clinical trials testing these 
concepts.
Perhaps more importantly, comparative and cross-
species analyses of tumors arising from the various 
models will help elucidate biological details about 
HGAs that will be informative for patient selection 
and stratification during these trials (Figure 2). Future 
investigations may address how mutations at multiple 
nodes of a pathway cooperate during gliomagenesis, the 
contribution of frequent HGA-associated mutations, such 
as IDH1 R132 which has not been modeled to date, and 
the identification of biomarkers of disease that can be 
used for predicting response to treatment and to follow 
tumor burden. GEMMs represent powerful tools with the 
potential to elucidate HGA biology and to inform the next 
generation of clinical trials. The judicious use of multiple 
models will accelerate these discoveries and offer hope to 
HGA patients who continue their fight for survival against 
vanishing odds.
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